Skip to main content
Terug
Watch Compare

GALECTIN THERAPEUTICS INC

Datakwaliteit: 83%
GALT
NASDAQ Manufacturing Chemicals
€ 2,56
▲ € 0,09 (3,64%)
6 months return
—
Momentum
Neutral
Free cash flow
-23,88 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio0,09
Interest Coverage-2,74

Waardering

PE (TTM)
-4,91
Onder sectorgemiddelde (-1,49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -23,88 M

Price History

Financiële Trends

Koersdoel Analisten

1 analist
Buy
+329.7%
upside to target
Huidig
€ 2,56
Consensus Target
€ 11,00
€ 11,00
Laag
€ 11,00
Hoog
Vooruitzicht
Forward WPA
-€ 0,33
Omzet Sch.
0,0

Winstverassingen

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -€ 0,06 · Rev Est: 0,0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -€ 0,15 -€ 0,12 -€ 0,13 -€ 0,08 — —
Estimate -€ 0,11 -€ 0,16 -€ 0,11 -€ 0,10 -€ 0,06 -€ 0,07
Verrassing -36,36% +25,00% -18,18% +20,00% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: N/A · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -30,84 M
ROE N/A ROA -216,64%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -23,88 M
ROIC N/A FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 0,09
Debt / Equity N/A Current Ratio 0,09
Interest Coverage -2,74 Asset Turnover N/A
Working Capital -123,72 M Tangible Book Value -125,30 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -4,91 · EV/EBITDA: N/A
P/E Ratio -4,91 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -15,77%
Market Cap 151,40 M Enterprise Value 139,88 M

Per Share

EPS: -0,48 · FCF/Share: -0,36
EPS (Diluted TTM) -0,48 Revenue / Share N/A
FCF / Share -0,36 OCF / Share -0,36
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 77,43% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 77,43%
SBC-Adj. FCF -25,85 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -30,84 M -47,05 M -41,07 M -38,78 M -30,53 M
EPS (Diluted) -0,48 -0,76 -0,74 -0,65 -0,52
Gross Profit — — — — —
Operating Income -20,09 M -42,43 M -38,07 M -38,35 M -30,18 M
EBITDA — — — — —
R&D Expenses 14,29 M 36,57 M 32,13 M 31,74 M 23,82 M
SG&A Expenses — — — — —
D&A — 0,0 0,0 0,0 0,0
Interest Expense 7,33 M 5,54 M 2,79 M 1,03 M 489.000,0
Income Tax 0,0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 19,53 M 17,50 M 28,20 M 21,29 M 41,83 M
Total Liabilities 145,73 M 120,57 M 88,44 M 53,48 M 39,21 M
Shareholders' Equity -127,92 M -104,79 M -61,96 M -33,92 M 893.000,0
Total Debt — — — — —
Cash & Equivalents 17,72 M 15,12 M 25,66 M 18,59 M 39,65 M
Current Assets 19,44 M 17,25 M 27,71 M 20,55 M 41,82 M
Current Liabilities 8,03 M 35,41 M 15,68 M 13,01 M 9,03 M

Sectorvergelijking

vs Manufacturing sector mediaan (1605 peers)
Metriek Aandeel Sector Mediaan
P/E -4,9 -1,5
P/B — 1,6
ROE % — -54,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

ETFs Holding This Stock
MEDX logo MEDX Horizon Kinetics Medical ETF
1,27% weight